Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $32.8 million.

  • Metagenomi's Cash & Equivalents rose 3048.13% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 3048.13%. This contributed to the annual value of $27.4 million for FY2024, which is 8052.25% down from last year.
  • Per Metagenomi's latest filing, its Cash & Equivalents stood at $32.8 million for Q3 2025, which was up 3048.13% from $26.8 million recorded in Q2 2025.
  • Metagenomi's Cash & Equivalents' 5-year high stood at $140.6 million during Q4 2023, with a 5-year trough of $25.1 million in Q3 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $51.6 million (2023), whereas its average is $63.2 million.
  • In the last 5 years, Metagenomi's Cash & Equivalents plummeted by 8052.25% in 2024 and then skyrocketed by 3048.13% in 2025.
  • Quarter analysis of 3 years shows Metagenomi's Cash & Equivalents stood at $140.6 million in 2023, then tumbled by 80.52% to $27.4 million in 2024, then increased by 19.67% to $32.8 million in 2025.
  • Its Cash & Equivalents stands at $32.8 million for Q3 2025, versus $26.8 million for Q2 2025 and $29.2 million for Q1 2025.